Deborah Persaud1, Kunjal Patel2, Brad Karalius2, Kaitlin Rainwater-Lovett1, Carrie Ziemniak1, Angela Ellis3, Ya Hui Chen1, Douglas Richman4, George K Siberry5, Russell B Van Dyke6, Sandra Burchett7, George R Seage2, Katherine Luzuriaga8. 1. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Epidemiology and the Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts. 3. Frontier Science and Technology Research Foundation, Inc, Buffalo, New York. 4. Department of Pathology, University of California, San Diego, La Jolla5Veterans Affairs San Diego Healthcare System, San Diego, California. 5. Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland. 6. Department of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana. 7. Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts. 8. Program in Molecular Medicine, Department of Pediatrics, University of Massachusetts Medical School, Worcester10Center for Clinical and Translational Science, University of Massachusetts Medical School, Worcester.
Abstract
IMPORTANCE: Combination antiretroviral therapy initiated within several weeks of human immunodeficiency virus (HIV) infection in adults limits proviral reservoirs that preclude HIV cure. Biomarkers of restricted proviral reservoirs may aid in the monitoring of HIV remission or cure. OBJECTIVES: To quantify peripheral blood proviral reservoir size in perinatally HIV-infected (PHIV+) adolescents and to identify correlates of limited proviral reservoirs. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional study including 144 PHIV+ youths (median age, 14.3 years) enrolled in the United States-based Pediatric HIV/AIDS Cohort Study and receiving durable (median duration, 10.2 years) combination antiretroviral therapy, stratified by age at virologic control. MAIN OUTCOMES AND MEASURES: The primary end point was peripheral blood mononuclear cell (PBMC) proviral load after virologic control at different ages. Correlations between proviral load and markers of active HIV production (ie, HIV-specific antibodies, 2-long terminal repeat circles) and markers of immune activation and inflammation were also assessed. RESULTS: Proviral reservoir size was markedly reduced in the PHIV+ youth who achieved virologic control before 1 year of age (4.2 [interquartile range, 2.6-8.6] copies per 1 million PBMCs) compared with those who achieved virologic control at 1 to 5 years of age (19.4 [interquartile range, 5.5-99.8] copies per 1 million PBMCs) or after 5 years of age (70.7 [interquartile range, 23.2-209.4] copies per 1 million PBMCs; P < .001). A proviral burden of less than 10 copies per 1 million PBMCs in PHIV+ youth was measured in 11 (79%), 20 (40%), and 13 (18%) participants with virologic control before 1 year, at 1 to 5 years, and after 5 years of age, respectively (P < .001). Lower proviral load was associated with undetectable 2-long terminal repeat circles (P < .001) and HIV-negative or indeterminate serostatus (P < .001) but not with concentrations of soluble immune activation markers CD14 and CD163. CONCLUSIONS AND RELEVANCE: Early effective combination antiretroviral therapy with prolonged virologic suppression after perinatal HIV infection leads to negligible peripheral blood proviral reservoirs in adolescence and is associated with negative or indeterminate HIV serostatus. These findings highlight the long-term effect of early effective control of HIV replication on biomarkers of HIV persistence in perinatal infection and the utility of HIV serostatus as a biomarker for small proviral reservoir size, although not necessarily for cure.
IMPORTANCE: Combination antiretroviral therapy initiated within several weeks of humanimmunodeficiency virus (HIV) infection in adults limits proviral reservoirs that preclude HIV cure. Biomarkers of restricted proviral reservoirs may aid in the monitoring of HIV remission or cure. OBJECTIVES: To quantify peripheral blood proviral reservoir size in perinatally HIV-infected (PHIV+) adolescents and to identify correlates of limited proviral reservoirs. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional study including 144 PHIV+ youths (median age, 14.3 years) enrolled in the United States-based Pediatric HIV/AIDS Cohort Study and receiving durable (median duration, 10.2 years) combination antiretroviral therapy, stratified by age at virologic control. MAIN OUTCOMES AND MEASURES: The primary end point was peripheral blood mononuclear cell (PBMC) proviral load after virologic control at different ages. Correlations between proviral load and markers of active HIV production (ie, HIV-specific antibodies, 2-long terminal repeat circles) and markers of immune activation and inflammation were also assessed. RESULTS: Proviral reservoir size was markedly reduced in the PHIV+ youth who achieved virologic control before 1 year of age (4.2 [interquartile range, 2.6-8.6] copies per 1 million PBMCs) compared with those who achieved virologic control at 1 to 5 years of age (19.4 [interquartile range, 5.5-99.8] copies per 1 million PBMCs) or after 5 years of age (70.7 [interquartile range, 23.2-209.4] copies per 1 million PBMCs; P < .001). A proviral burden of less than 10 copies per 1 million PBMCs in PHIV+ youth was measured in 11 (79%), 20 (40%), and 13 (18%) participants with virologic control before 1 year, at 1 to 5 years, and after 5 years of age, respectively (P < .001). Lower proviral load was associated with undetectable 2-long terminal repeat circles (P < .001) and HIV-negative or indeterminate serostatus (P < .001) but not with concentrations of soluble immune activation markers CD14 and CD163. CONCLUSIONS AND RELEVANCE: Early effective combination antiretroviral therapy with prolonged virologic suppression after perinatal HIV infection leads to negligible peripheral blood proviral reservoirs in adolescence and is associated with negative or indeterminate HIV serostatus. These findings highlight the long-term effect of early effective control of HIV replication on biomarkers of HIV persistence in perinatal infection and the utility of HIV serostatus as a biomarker for small proviral reservoir size, although not necessarily for cure.
Authors: Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano Journal: Nat Med Date: 2003-05-18 Impact factor: 53.440
Authors: J M Binley; A Trkola; T Ketas; D Schiller; B Clas; S Little; D Richman; A Hurley; M Markowitz; J P Moore Journal: J Infect Dis Date: 2000-08-01 Impact factor: 5.226
Authors: William T Shearer; Howard M Rosenblatt; Rebecca S Gelman; Rebecca Oyomopito; Susan Plaeger; E Richard Stiehm; Diane W Wara; Steven D Douglas; Katherine Luzuriaga; Elizabeth J McFarland; Ram Yogev; Mobeen H Rathore; Wende Levy; Bobbie L Graham; Stephen A Spector Journal: J Allergy Clin Immunol Date: 2003-11 Impact factor: 10.793
Authors: Saurabh Mehandru; Michael A Poles; Klara Tenner-Racz; Amir Horowitz; Arlene Hurley; Christine Hogan; Daniel Boden; Paul Racz; Martin Markowitz Journal: J Exp Med Date: 2004-09-13 Impact factor: 14.307
Authors: Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek Journal: J Exp Med Date: 2004-09-13 Impact factor: 14.307
Authors: Alfredo Tagarro; Man Chan; Paola Zangari; Bridget Ferns; Caroline Foster; Anita De Rossi; Eleni Nastouli; María A Muñoz-Fernández; Diana Gibb; Paolo Rossi; Carlo Giaquinto; Abdel Babiker; Claudia Fortuny; Riccardo Freguja; Nicola Cotugno; Ali Judd; Antoni Noguera-Julian; María Luisa Navarro; María José Mellado; Nigel Klein; Paolo Palma; Pablo Rojo Journal: J Acquir Immune Defic Syndr Date: 2018-10-01 Impact factor: 3.731
Authors: Zabrina L Brumme; Hanwei Sudderuddin; Carrie Ziemniak; Katherine Luzuriaga; Bradley R Jones; Jeffrey B Joy; Coleen K Cunningham; Thomas Greenough; Deborah Persaud Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Steven G Deeks; Sharon R Lewin; Anna Laura Ross; Jintanat Ananworanich; Monsef Benkirane; Paula Cannon; Nicolas Chomont; Daniel Douek; Jeffrey D Lifson; Ying-Ru Lo; Daniel Kuritzkes; David Margolis; John Mellors; Deborah Persaud; Joseph D Tucker; Françoise Barre-Sinoussi; Galit Alter; Judith Auerbach; Brigitte Autran; Dan H Barouch; Georg Behrens; Marina Cavazzana; Zhiwei Chen; Éric A Cohen; Giulio Maria Corbelli; Serge Eholié; Nir Eyal; Sarah Fidler; Laurindo Garcia; Cynthia Grossman; Gail Henderson; Timothy J Henrich; Richard Jefferys; Hans-Peter Kiem; Joseph McCune; Keymanthri Moodley; Peter A Newman; Monique Nijhuis; Moses Supercharger Nsubuga; Melanie Ott; Sarah Palmer; Douglas Richman; Asier Saez-Cirion; Matthew Sharp; Janet Siliciano; Guido Silvestri; Jerome Singh; Bruno Spire; Jeffrey Taylor; Martin Tolstrup; Susana Valente; Jan van Lunzen; Rochelle Walensky; Ira Wilson; Jerome Zack Journal: Nat Med Date: 2016-07-11 Impact factor: 53.440